Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Benzinga
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
